Immucell 

$9.85
4
-$0.15-1.5% 16:38 Today

Statistics

Day High
9.97
Day Low
9.81
52W High
12.1
52W Low
4.52
Volume
5,966
Avg. Volume
28,938
Mkt Cap
89.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.31
-0.14
0.04
0.21
Expected EPS
N/A
Actual EPS
N/A

Financials

-3.76%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
27.64MRevenue
-1.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ICCC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zoetis
ZTS
Mkt Cap31.96B
Zoetis is a global leader in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines, competing directly with Immucell's focus on bovine and dairy health products.
Elanco Animal Health
ELAN
Mkt Cap12.05B
Elanco Animal Health Incorporated operates in the same sector, providing a range of health products for animals, which puts it in direct competition with Immucell's product offerings.
Idexx Laboratories
IDXX
Mkt Cap43.72B
IDEXX Laboratories, Inc. specializes in diagnostics and software for pets, livestock, and poultry, overlapping with Immucell's market in animal health diagnostics.
Phibro Animal Health
PAHC
Mkt Cap1.53B
Phibro Animal Health Corporation offers a broad range of animal health and nutritional products, competing in the same space as Immucell, especially in the area of health products for livestock.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc., through its animal health division, produces vaccines and health products for animals, making it a competitor in the animal health sector alongside Immucell.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc., with its portfolio of animal health products through Zoetis, competes in the same industry, offering similar products for animal care and health.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories, while primarily focused on human healthcare, also offers veterinary products that compete in the broader market of animal health, overlapping with Immucell's market.
Novartis
NVS
Mkt Cap292.35B
Novartis International AG, through its operations in animal health, competes in the global market for veterinary products, including those offered by Immucell.

About

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Show more...
CEO
F. Olivier Te Boekhorst
Employees
73
Country
United States
ISIN
US4525253062
WKN
000885825

Listings

0 Comments

Share your thoughts

FAQ

What is Immucell stock price today?
The current price of ICCC is $9.85 USD — it has decreased by -1.5% in the past 24 hours. Watch Immucell stock price performance more closely on the chart.
What is Immucell stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immucell stocks are traded under the ticker ICCC.
Is Immucell stock price growing?
ICCC stock has fallen by -0.8% compared to the previous week, the month change is a -10.93% fall, over the last year Immucell has showed a +51.23% increase.
What is Immucell market cap?
Today Immucell has the market capitalization of 89.46M
When is the next Immucell earnings date?
Immucell is going to release the next earnings report on November 12, 2026.
What is Immucell revenue for the last year?
Immucell revenue for the last year amounts to 27.64M USD.
What is Immucell net income for the last year?
ICCC net income for the last year is -1.04M USD.
How many employees does Immucell have?
As of September 04, 2026, the company has 73 employees.
In which sector is Immucell located?
Immucell operates in the Health & Wellness sector.
When did Immucell complete a stock split?
Immucell has not had any recent stock splits.
Where is Immucell headquartered?
Immucell is headquartered in PORTLAND, United States.